Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years. Shares are down 19% over the ...

Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year. The drugmaker has set a ...

Altria's dividend yield is 7%, even as it trades at 11 times estimated earnings over the next 12 months – a 40% premium to ...

With the end of the pandemic, sales of Pfizer’s COVID products, Comirnaty and Paxlovid, came down to around $11 billion in 2024 from $56.7 billion in 2022. In 2025, Pfizer’s revenues from ...

Paxlovid is used to treat adults and children over 12 years old with mild-to-moderate coronavirus disease who are at high risk for progression to severe disease. Developed by Pfizer, Paxlovid was ...

Market pessimism has undervalued Pfizer and Rexford, both offering high yields and overlooked growth potential. Learn more on ...

Awards will also recognise innovation, rising stars from the ECP community, and individuals who have made outstanding ...

Major pharmaceutical companies around the world—and increasingly in South Korea—are turning to artificial intelligence (AI) ...